Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada

The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Bridgewest Group launches new sterile injectable CDMO NovaCina

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

SK Capital completes acquisition of Apotex

Philips and Northwell Health partner to standardize patient monitoring across the enterprise

New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes

FDA approves Merck’s Keytruda in combination with Padcev for treatment of metastatic urothelial cancer

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients

TSCS team met All India Imam Organization Chief to discuss on thalassemia eradication in India

Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease

GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme

SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties

Evonik starts construction of US$220 million lipid innovation center in Lafayette

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness